Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review.
Document Type
Article
Publication Date
12-2024
Publication Title
Current oncology reports
Abstract
PURPOSE OF REVIEW: As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
RECENT FINDINGS: While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms. In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies.
Volume
26
Issue
12
First Page
1651
Last Page
1663
Recommended Citation
Kalsi S, Galenkamp AL, Singh R, Khosla AA, McGranaghan P, Cintolo-Gonzalez J. Talimogene laherparepvec (t-vec) and emerging intralesional immunotherapies for metastatic melanoma: a review. Curr Oncol Rep. 2024 Dec;26(12):1651-1663. doi: 10.1007/s11912-024-01611-9. PMID: 39602056.
DOI
10.1007/s11912-024-01611-9
ISSN
1534-6269
PubMed ID
39602056